European Psychiatry - Volume 33 - March 2016

674 / 812

S670 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
EV1004
Treating ADHD in people with
intellectual disabilities
K. Courtenay
UCL, Department Mental Health Sciences, London, United Kingdom
Objectives Attention Deficit Hyperactivity Disorder (ADHD) is
more prevalent in people with intellectual disabilities (ID). Drug
therapy is the primary treatment for ADHD targeting the core signs
of inattention, impulsivity, and hyperactivity (NICE 2013). Knowl-
edge on ADHD has been gleaned from studies in children and
childrenwith ID. Peoplewith ID have comorbid disorders for exam-
ple, autism and epilepsy that can complicate the management of
ADHD. Knowledge of the effects of treatment is essential in manag-
ingADHD inpeoplewith ID. The current evidence on the application
of drug therapy for ADHD in ID is described.
Method A literature review of publications in English language
was undertaken.
Results Using medication to treat ADHD is effective in treat-
ing the signs of ADHD in people with ID. The response rates in
ID to drug therapy for ADHD approximates to 55% that is lower
than in the general population. People with ID experience more
side effects from medication that can lead to withdrawal from
treatment. Guidelines exist internationally on the appropriate pre-
scribing of medication. Methylphenidate, a psycho-stimulant drug
is the drug of first choice. Atomxetine, a non-stimulant drug, is
effective in people with ID.
Conclusions ADHD in people with ID is treatable but clinicians
need to be knowledgeable and skilled in managing the disorder
in people with ID. Newer drugs could offer more because of their
different profile of more tolerable side effects.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EV1005
Analysis of the diagnoses of patients
treated with palmitate paliperidone
C. Diago Labrador ∗ . Álvarez Montoya , T. Ruano Hernández
Clínica privada, Clínica privada, Algeciras, Spain
∗ Corresponding author.
Objectives Review of the diagnoses of the treated patients with
palmitate paliperidone for one year in a mental health unit, as well
as some of their key sociodemographic characteristics, the length
of the hospital stay and the average treatment according to clinical
diagnosis.
Methods Descriptive epidemiological study including patients
admitted to our hospital. It covers the period from January 2014
to December 2014.
Results For the period between January and December, a total of
315 patients were admitted in our mental health hospital unit, of
which 45 were treated with paliperidone palmitate. The diagnosis
were: schizophrenia (25 patients; 55.56%), schizoaffective disorder
(7 patients; 15.56%), delusional disorder (5 patients; 11.11%), bipo-
lar disorder (1 patient; 2.22%), personality disorder (2 patients;
4.44%), obsessive-compulsive disorder (1 patient; 2.22%), organic
brain disorder (1 patient; 2.22%), schizophreniform disorder (1
patient; 2.22%) andmental retardation (1 patient; 2.22%). Themean
age of patients was 35.7 years old. The most common marital sta-
tus was unmarried state (30 patients; 66.6%). The average stay per
hospital admission was 19.33 days. The most abused drugs were
tobacco (31 patients; 68.8%). Themean dose of paliperidone palmi-
tate was 137.5mg. Schizophrenic patients need higher doses of
treatment.
Conclusions A significant improvement in functionality was
observed in our patients. What’s proven efficacy and good
tolerability and adherence, so we consider paliperidone palmitate
as a drug of first choice in the treatment of schizophrenia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1006
Nalmefene and alcohol use disorder
M.D. Díaz Pi˜neiro ∗ . Gutiérrez Ortega ,
M. Mateos Agut , E. Martín Martínez , B. Sanz Cid
University Hospital of Burgos, Psychiatry, Burgos, Spain
∗ Corresponding author.
Introduction Psychopharmacology study.
Objective To evaluate Nalmefene effectiveness in clinical practice
in patients diagnosed with alcohol use disorder.
Method Descriptive, prospective and observational study with
patients diagnosed with alcohol use disorder, treated with Nalme-
fene during 6 months.
Results Twenty-seven patients (9 women and 18 men); average
age: 47.92. A total of 64.28% with F10 as an exclusive main diagno-
sis. Drink urge perception at the beginning: 6.37 points over 10.6
months later, 3.25 points. Loss of alcohol drinking control percep-
tion at the beginning: 6.03 points over 10. Six months later, it is
reduced down to 2.37 points. GGT reduction (from 107.18 to 36.5
U.I./L) and Mean Corpuscular Volume reduction (from 90.2 to 88.9
fl). The average of days/month with binge drinking at the begin-
ning was 16.18 SD (standard drinks); and monthly total of alcohol
consumption is 182.75 SD. After a month: 4.6 days and 66.52 SD.
After 6 months, it decreases to 4 days/month and 63.3 SD. The
results of the Rhode Island Change Assessment scale are: 7.4% in
pre-contemplation stage, 70.37% contemplation stage, 3.7% action
stage and 18.5% in maintenance stage. Six months later: 75% con-
templation, 12.5% action and 12.5% maintenance stage. The main
side effects were: nausea and vomiting, 22.22% at the beginning
and 12.5% that persist with intakes; sexual side effects in 22.22%
throughout the treatment; the 14.8% report increased sleeping and
dreaming, 14.8% report restlessness, after six months drowsiness
prevails with a 18%. At first, orthostatic dizziness appears in a 14.8%,
disappearing 4 weeks later.
Conclusion Nalmefene is effective in reducing alcohol consump-
tion, with few side effects and good acceptance.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1007
Antipsychotic polypharmacy at the
clinic of psychiatry, clinical centre of
Serbia
N. Divac ∗, A. Damjanovic , R. Stojanovic , K. Savic Vujovic ,
B. Letunica , M. Prostran
1 Faculty of Medicine, University of Belgrade, Department of
Pharmacology-Clinical Pharmacology and Toxicology, Belgrade,
Serbia
2 Clinical Centre of Serbia, Clinic of Psychiatry, Belgrade, Serbia
3 University of Belgrade, Faculty of Medicine, Belgrade, Serbia
∗ Corresponding author.
Introduction Antipsychotic polypharmacy is not supported by
current guidelines. However, it is often present in practice. A com-
mon reason for this is to gain a greater, faster therapeutic response
and reduce the doses of individual drugs, thus reducing the adverse
effects.
Aims and Objectives The aim of this study is to analyze the preva-
lence of antipsychotic polypharmacy at the Clinic of Psychiatry,